Elicio Therapeutics to Present at the Bank of America Healthcare Conference

Rhea-AI Summary

Elicio Therapeutics (Nasdaq: ELTX) will present at the Bank of America Healthcare Conference in Las Vegas on May 14, 2026 at 12:20 PM ET.

Presenters include CEO Robert Connelly, CMO Christopher Haqq, CSO Pete DeMuth, and CSFO Preetam Shah. A live webcast and 90-day replay are available via the company’s Events page. 1×1 meetings are arranged through Bank of America representatives.

News Market Reaction – ELTX

+2.91%

+2.91% Session close to close

In the Apr 30 session, ELTX gained 2.91%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights management’s planned participation in the Bank of America Healthcare Co...

Analysis

This announcement highlights management’s planned participation in the Bank of America Healthcare Conference, with a company presentation on May 14, 2026 at 12:20 PM ET and a webcast available for 90 days. It follows recent financial, clinical, and financing disclosures, including an effective shelf for up to $400,000,000 in securities and an ATM program. Investors may watch for any new clinical or strategic details shared during the conference.

Key Figures

Conference dates: May 12-14, 2026 Presentation date: May 14, 2026 Presentation time: 12:20 PM ET +1 more

4 metrics

Conference dates May 12-14, 2026 Bank of America Healthcare Conference dates

Presentation date May 14, 2026 Scheduled company presentation date

Presentation time 12:20 PM ET Scheduled start time for company presentation

Webcast availability 90 days Replay available on Events page following presentation

Historical Context

5 past events · Latest: Apr 16 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 16	Inducement grants	Neutral	+7.0%	Announcement of 21,210 inducement stock options under 2024 plan.
Mar 17	Inducement grants	Neutral	+0.2%	Grant of 1,600 inducement stock options to a new employee.
Mar 12	Earnings report	Positive	+11.9%	Full-year 2025 financials and Phase 2 AMPLIFY-7P clinical update.
Feb 25	Conference presentation	Neutral	+10.3%	Planned presentation at TD Cowen 46th Annual Health Care Conference.
Feb 18	Inducement grants	Neutral	+3.4%	Grant of 30,300 inducement stock options to a new hire.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent routine corporate updates and conference appearances have often coincided with positive single-day moves, though magnitudes vary.

Recent Company History

Over the past few months, Elicio has issued several routine updates, including multiple inducement grant announcements on Feb 18, Mar 17, and Apr 16, 2026, plus a conference presentation notice on Feb 25, 2026. The company also reported full-year 2025 financials and clinical updates on Mar 12, 2026. These items, while largely operational and informational, were often followed by positive single-day price reactions, framing today’s conference participation news within an ongoing flow of corporate communications.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOSTON, April 30, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that Robert Connelly, Chief Executive Officer, Christopher Haqq, MD, PhD, Executive Vice President, Head of Research and Development and Chief Medical Officer, Pete DeMuth, PhD, Chief Scientific Officer, and Preetam Shah, MBA, PhD, Chief Strategy and Financial Officer, will participate in the upcoming Bank of America Healthcare Conference, taking place May 12-14, 2026, in Las Vegas, NV.

Bank of America Healthcare Conference
Format: Company presentation
Date: Thursday, May 14, 2026
Time: 12:20 PM ET

The live webcast and replay of the presentation will be available HERE and on Elicio’s Events page for 90 days following the event.

If you are interested in arranging a 1×1 meeting with management at the conference, please contact your Bank of America representative.

About Elicio Therapeutics

Elicio Therapeutics, Inc. (Nasdaq: ELTX) is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of high-prevalence cancers, including mKRAS-positive pancreatic and colorectal cancers. Elicio intends to build on recent clinical successes in the personalized cancer immunotherapy space to develop effective, off-the-shelf immunotherapies. Elicio’s Amphiphile (“AMP”) technology aims to enhance the education, activation and amplification of cancer-specific T cells relative to conventional immunotherapy strategies, with the goal of promoting durable cancer immunosurveillance in patients. Elicio’s ELI-002 7P lead program is an off-the-shelf immunotherapy candidate targeting the most common KRAS mutations, which drives approximately 25% of all solid tumors. Elicio intends to expand ELI-002 7P clinical development not only for treatment in adjuvant pancreatic ductal adenocarcinoma (“PDAC”), but also in neoadjuvant and metastatic PDAC settings, and for other mKRAS-positive cancers. Off-the-shelf immunotherapy approaches have the potential benefits of low cost, rapid commercial scale manufacturing, and rapid availability of drug to patients especially in neo-adjuvant settings and for prophylaxis in high-risk patients, contrary to personalized immunotherapy approaches. ELI-002 is being studied in an ongoing, randomized clinical trial in patients with mKRAS-positive PDAC who completed standard therapy but remain at high risk of relapse. ELI-002 also has been studied in patients with mKRAS-positive colorectal cancer (“CRC”) in Phase 1 studies. The updated AMPLIFY-201 Phase 1 data for PDAC and CRC was presented at the ESMO Immuno-Oncology Congress 2024 and included a 16.3-month median recurrence-free survival and 28.9-month median overall survival for the full study population. Elicio’s pipeline includes additional off-the-shelf therapeutic cancer immunotherapy candidates, including ELI-007 and ELI-008, that target BRAF-driven cancers and p53 hotspot mutations, respectively. For more information, please visit www.elicio.com.

Investor Relations Contact
Brian Ritchie
LifeSci Advisors
(212) 915-2578
britchie@lifesciadvisors.com

FAQ

When will Elicio Therapeutics (ELTX) present at the Bank of America Healthcare Conference?

Elicio will present on May 14, 2026 at 12:20 PM ET. According to the company, the presentation is part of the Bank of America Healthcare Conference in Las Vegas and includes senior management participation.

Who from Elicio Therapeutics (ELTX) will speak at the May 2026 Bank of America Healthcare Conference?

Speakers include CEO Robert Connelly, CMO Christopher Haqq, CSO Pete DeMuth, and CSFO Preetam Shah. According to the company, these executives will deliver the company presentation and be available for related conference engagements.

How can investors watch Elicio Therapeutics (ELTX) presentation at the conference?

A live webcast and replay will be available on the company Events page for 90 days. According to the company, the webcast link is posted on its Events page and the presentation replay will remain accessible for three months.

Can investors arrange 1x1 meetings with Elicio Therapeutics (ELTX) management at the conference?

Yes, 1×1 meetings can be arranged through Bank of America representatives. According to the company, interested parties should contact their Bank of America representative to request a one-on-one meeting with management at the event.

Where will Elicio Therapeutics (ELTX) host its conference presentation replay after May 14, 2026?

The replay will be hosted on Elicio’s Events page for 90 days following the event. According to the company, investors can access the replay via the Events page and the provided webcast link for three months.